Quantum BioPharma has announced the completion of oral dosing in both 180-day toxicity and toxicokinetic studies for its experimental drug, Lucid-21-302 (Lucid-MS). 

 

The studies are a critical step toward the company’s Investigational New Drug (IND) application with the US FDA and the design of a Phase 2 trial targeting people with multiple sclerosis (MS).

 

“We are very pleased that dosing is now complete in both 180-day chronic toxicity studies. These studies allow us to advance the Lucid-MS drug development program as they are critical components to the IND application with the FDA,” said Dr Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.

 

Anthony Durkacz, Founder and executive co-chairman of Quantum BioPharma, added, “By completing these 180-day toxicity studies, we are now two important steps closer to initiating the Phase 2 trial of Lucid-MS in people with multiple sclerosis. We are very excited about the potential of this new, first-in-class treatment to prevent disease progression and inhibit demyelination in MS.”

 

Lucid-MS represents a potential breakthrough in the treatment of MS, with Quantum BioPharma advancing its pipeline of innovative therapies for neurodegenerative, metabolic, and alcohol misuse disorders.